Optimized 4,5-Diarylimidazoles as Potent/Selective Inhibitors of Protein Kinase CK1δ and Their Structural Relation to p38α MAPK
作者:Jakob Halekotte、Lydia Witt、Chiara Ianes、Marc Krüger、Mike Bührmann、Daniel Rauh、Christian Pichlo、Elena Brunstein、Andreas Luxenburger、Ulrich Baumann、Uwe Knippschild、Joachim Bischof、Christian Peifer
DOI:10.3390/molecules22040522
日期:——
we report on design and characterization of optimized 4,5-diarylimidazoles as highly effective ATP-competitive inhibitors of CK1δ with compounds 11b (IC50 CK1δ = 4 nM, IC50 CK1ε = 25 nM), 12a (IC50 CK1δ = 19 nM, IC50 CK1ε = 227 nM), and 16b (IC50 CK1δ = 8 nM, IC50 CK1ε = 81 nM) being among the most potent CK1δ-targeting agents published to date. Inhibitor compound 11b, displaying potential as a pharmacological
蛋白激酶CK1δ参与诸如阿尔茨海默氏病,肌萎缩性侧索硬化症,家族性晚期睡眠相综合征和癌症等严重疾病的发病机理,极大地提高了对开发用于治疗应用和基础研究的有效小分子抑制剂的兴趣。不幸的是,由于存在六个进化上保守的人CK1成员,这些成员具有相似,不同或什至相反的生理和病理生理学含义,因此CK1异构体特异性化合物的设计已被证明非常复杂。因此,到目前为止,仅报道了几种有效且选择性的CK1δ抑制剂,急需在结构上不同的方法来建立SAR,从而可以完全区分CK1亚型和相关的p38αMAPK。在这项研究中,我们报告了作为化合物1b(IC50CK1δ= 4 nM,IC50CK1ε= 25 nM),12a(IC50CK1δ= 19 nM, IC50CK1ε= 227 nM)和16b(IC50CK1δ= 8 nM,IC50CK1ε= 81 nM)是迄今为止最有效的CK1δ靶向药物。在药理学工具中显示出潜力的抑制剂